Class II transactivator-induced expression of HLA-DOβ in Hela cells

Tissue Antigens

Volumn 60, Issue 5, 2002, Pages 372-382

  Khalil, H ^a   Deshaies, F ^a   Bellemare Pelletier, A ^a   Brunet, A ^a   Faubert, A ^a   Azar, G A ^a   Thibodeau, Jacques ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

CIITA; HeLa; HLA DM; HLA DO; MHC

Indexed keywords

EPITOPE; HLA ANTIGEN CLASS 2; HLA DM ANTIGEN; HLA DO ANTIGEN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSACTIVATOR PROTEIN; TRANSACTIVATOR PROTEIN CIITA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CONTROLLED STUDY; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HELA CELL; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; LYSOSOME; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN MOTIF; SIGNAL TRANSDUCTION; SPLEEN CELL; TRANSACTIVATION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; BURKITT LYMPHOMA; CELL LINE; FLOW CYTOMETRY; HELA CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-D ANTIGENS; HUMANS; MICE; MICROSCOPY, CONFOCAL; NUCLEAR PROTEINS; TRANS-ACTIVATORS;

EID: 0036867748     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0039.2002.600504.x     Document Type: Article

References (58)

1. Cresswell P. Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol 1994: 12: 259-93.
2. Roche PA, Marks MS, Cresswell P. Identification of the HLA class II-invariant chain complex as a nine subunit transmembrane glycoprotein. Nature 1991: 354: 392-4.
3. Lamb CA, Cresswell P. Assembly and transport properties of invariant chain trimers and HLA-DR-invariant chain complexes. J Immunol 1992: 148: 3478-82.
4. Pieters J, Bakke O, Dobberstein B. The MHC class II-associated invariant chain contains two endosomal targeting signals within its cytoplasmic tail. J Cell Sci 1993: 106: 831-46.
5. Odorizzi CG, Trowbridge IS, Xue L, Hopkins CR, Davis CD, Collawn JF. Sorting signals in the MHC class II invariant chain cytoplasmic tail and transmembrane region determine trafficking to an endocytic processing compartment. J Cell Biol 1994: 126: 317-30.
6. Riberdy JM, Newcomb JR, Surman MJ, Barbosa JA, Cresswell P. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature 1992: 360: 474-7.
7. Alfonso C, Karlsson L. Nonclassical MHC class II molecules. Annu Rev Immunol 2000: 18: 113-42.
8. Alfonso C, Liljedahl M, Winqvist O et al. The role of H2-O and HLA-DO in major histocompatibility complex class II-restricted antigen processing and presentation. Immunol Rev 1999: 172: 255-66.
9. Kropshofer H, Hammerling GJ, Vogt AB. The impact of the non-classical MHC proteins HLA-DM and HLA-DO on loading of MHC class II molecules. Immunol Rev 1999: 172: 267-78.
10. Young JA, Trowsdale J. The HLA-DNA (DZA) gene is correctly expressed as a 1.1 kb mature mRNA transcript. Immunogenetics 1990: 31: 386-8.
11. Tonnelle C, DeMars R, Long EO. DOβ? A new β chain gene in HLA-D with a distinct regulation of expression. EMBO J 1985: 4: 2839-47.
12. Servenius B, Rask L, Peterson PA. Class II genes of the human major histocompatibility complex. The DO beta gene is a divergent member of the class II beta gene family. J Biol Chem 1987: 262: 8759-66.
13. Liljedahl M, Kuwana T, Fung-Leung WP, Jackson M, Peterson PA, Karlsson L. HLA-DO is a lysosomal resident which requires association with HLA-DM for efficient intracellular transport. EMBO J 1996: 15: 4817-24.
14. Weber DA, Evavold BD, Jensen PE. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science 1996: 274: 618-20.
15. Denzin LK, Cresswell P. HLA-DM induces CLIP dissodation from MHC class II αβ dimers and facilitates peptide loading. Cell 1995: 82: 155-65.
16. Roche PA. HLA-DM: An in vivo facilitator of MHC class II peptide loading. Immunity 1995: 3: 259-62.
17. Van Ham SM, Grueneberg U, Malcherek G, Broeker I, Melms A, Trowsdale J. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs. J Exp Med 1996: 184: 2019-24.
18. Kropshofer H, Vogt AB, Moldenhauer G, Hammer J, Blum JS, Hammerling GJ. Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBO J 1996: 15: 6144-54.
19. Sherman MA, Weber DA, Jensen PE. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide. Immunity 1995: 3: 197-205.
20. Sloan VS, Cameron P, Porter G et al. Mediation by HLA-DM of dissociation of peptides from HLA- DR. Nature 1995: 375: 802-6.
21. Douek DC, Altmann DM. HLA-DO is an intracellular class II molecule with distinctive thymic expression. Int Immunol 1997: 9: 355-64.
22. Karlsson L, Surh CD, Sprent J, Peterson PA. A novel class II MHC molecule with unusual tissue distribution. Nature 1991: 351: 485-8.
23. Wake CT, Flavell RA. Multiple mechanisms regulate the expression of murine immune response genes. Cell 1985: 42: 623-8.
24. Denzin LK, Sant' Angelo DB, Hammond C, Surman MJ, Cresswell P. Negative regulation by HLA-DO of MHC Class II-restricted antigen processing. Science 1997: 278: 106-9.
25. Van Ham SM, Tjin EPM, Lillemeir BF et al. HLA-DO is a negative regulator of HLA-DM-mediated MHC class II peptide loading. Current Biol 1997: 7: 950-7.
26. Liljedahl M, Winqvist O, Surh CD et al. Altered antigen presentation in mice lacking H2-O. Immunity 1998: 8: 233-43.
27. van Ham M, van Lith M, Griekspoor A, Neefjes J. What to do with HLA-DO? Immunogenetics 2000: 51: 765-70.
28. Trowsdale J, Kelly A. The Human HLA class II α chain DZα is distinct from genes in the DP, DQ and DR subregions. EMBO J 1985: 4: 2231-7.
29. Steimle V, Siegrist C-A, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 1994: 265: 106-9.
30. Mach B, Steimle V, Martinez-Soria E, Reith W. Regulation of MHC class II genes: Lessons from a disease. Annu Rev Immunol 1996: 14: 301-31.
31. Taxman DJ, Cressman DE, Ting JP. Identification of class II transcriptional activator-induced genes by representational difference analysis: Discoordinate regulation of the DN alpha/DO beta heterodimer. J Immunol 2000: 165: 1410-6.
32. Ponzoni M, Guarnaccia F, Corrias MV, Cornaglia-Ferraris P. Uncoordinate induction and differential regulation of HLA class-I and class-II expression by gamma-interferon in differentiating human neuroblastoma cells. Int J Cancer 1993: 55: 817-23.
33. Nagarajan UM, Lochamy J, Chen X et al. Class II transactivator is required for maximal expression of HLA-DOB in B Cells. J Immunol 2002: 168: 1780-6.
34. DeMars R, Chang CC, Shaw S, Reitnauer PJ, Sondel PM. Homozygous deletions that simultaneously eliminate expression of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigens. Hum Immunol 1984: 11: 77-97.
35. Klein G, Sugden B, Leibold W, Menezes J. Infection of EBV-genome-negative and -positive human lymphoblastoid cell lines with biologically different preparations of EBV. Intervirology 1974: 3: 232-44.
36. Menezes J, Leibold W, Klein G, Clements G. Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine 1975: 22: 276-84.
37. Chin KC, Li GG, Ting JP. Importance of acidic, proline/serine/threonine-rich, and GTP-binding regions in the major histocompatibility complex class II transactivator: Generation of transdominant-negative mutants. Proc Natl Acad Sci U S A 1997: 94: 2501-6.
38. Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973: 52: 456-67.
39. Brunet A, Samaan A, Deshaies F, Kindt TJ, Thibodeau J. Functional characterization of a lysosomal sorting motif in the cytoplasmic tail of HLA-DObeta. J Biol Chem 2000: 275: 37062-71.
40. Panina-Bordignon P, Fu X, Lanzavecchia A, Karr RW. Identification of HLA-DR α chain residues critical for binding of the toxic shock syndrome toxin superantigen. J Exp Med 1992: 176: 1779-84.
41. Radka SF, Machamer CE, Cresswell P. Analysis of monoclonal antibodies reactive with human class II beta chains by two-dimensional electrophoresis and western blotting. Hum Immunol 1984: 10: 177-88.
42. Denzin LK, Robbins NF, Carboy-Newcomb C, Cresswell P. Assembly and intracellular transport of HLA-DM and correction of the class II antigen-processing defect in T2 cells. Immunity 1994: 1: 595-606.
43. Chong P, Chan N, Kandil A et al. A strategy for rational design of fully synthetic glycopeptide conjugate vaccines. Infect Immun 1997: 65: 4918-25.
44. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975: 256: 495-7.
45. Lietzke R, Unsicker K. A statistical approach to determine monoclonality after limiting cell plating of a hybridoma clone. J Immunol Meth 1985: 76: 223-8.
46. Lavoie PM, Thibodeau J, Cloutier I, Busch R, Sekaly RP. Selective binding of bacterial toxins to major histocompatibility complex class II-expressing cells is controlled by invariant chain and HLA-DM. Proc Natl Acad Sci U S A 1997: 94: 6892-7.
47. Thibodeau J, Lavoie PM, Samaan A, Corre JP, Sékaly RP, Cazenave PA. Conserved structural features between HLA-DOβ and -DRβ. Mol Immunol 1998: 35: 885-93.
48. Samaan A, Thibodeau J, Mahana W, Castellino F, Cazenave PA, Kindt TJ. Cellular distribution of a mixed MHC class II heterodimer between DRa and a chimeric DOβ chain. Int Immunol 1999: 11: 99-111.
49. Heilker R, Spiess M, Crottet P. Recognition of sorting signals by clathrin adaptors. Bioessays 1999: 21: 558-67.
50. Roucard C, Thomas C, Pasquier MA et al. In vivo and in vitro modulation of HLA-DM and HLA-DO is induced by B lymphocyte activation. J Immunol 2001: 167: 6849-58.
51. Copier J, Kleijmeer MJ, Ponnambalam S et al. Targeting signal and subcellular compartments involved in the intracellular trafficking of HLA-DMB. J Immunol 1996: 157: 1017-27.
52. Lindstedt R, Liljedahl M, Peleraux A, Peterson PA, Karlsson L. The MHC class II molecule H2-M is targeted to an endosomal compartment by a tyrosine-based targeting motif. Immunity 1995: 3: 561-72.
53. Marks MS, Roche PA, van Donselaar E, Woodruff L, Peters PJ, Bonifacino JS. A lysosomal targeting signal in the cytoplasmic tail of the β chain directs HLA-DM to MHC class II compartments. J Cell Biol 1995: 131: 351-69.
54. Chang CH, Guerder S, Hong SC, Van Ewijk W, Flavell RA. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression. Immunity 1996: 4: 167-78.
55. Masternak K, Muhlethaler M, Ottet A et al. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev 2000: 14: 1156-66.
56. Voliva CF, Jabrane-Ferrat N, Peterlin BM. The function of the octamer-binding site in the DRA promoter. Immunogenetics 1995: 43: 20-6.
57. Martin BK, Frelinger JG, Ting JP. Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth. J Immunol 1999: 162: 6663-70.
58. Robadey C, Ammerlaan W, Muller C et al. The processing routes determined by negatively charged residues in DR1-restricted T cell determinants. J Immunol 1997: 159: 3238-46.